Medpace Holdings, Inc. (MEDP) Debt to Assets Ratio: 0.13%
The debt to assets ratio for Medpace Holdings, Inc. (MEDP) is 0.13% as of Wednesday, June 17, 2026.
MEDP Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.13%
MEDP Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.18B | 0.13% |
| The Cooper Companies, Inc. (COO)vs › | $13.14B | 0.22% |
| Solventum Corporation (SOLV)vs › | $13.26B | 0.35% |
| DaVita Inc. (DVA)vs › | $13.46B | 0.86% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 0.02% |
| Revvity, Inc. (RVTY)vs › | $11.29B | 0.29% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.42% |
| Baxter International Inc. (BAX)vs › | $10.19B | 0.50% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 0.29% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 0.43% |
Leverage Ratios Comparison
Debt/Assets
0.1%
Debt/Equity
0.55
Current Ratio
0.74
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Medpace Holdings, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Medpace Holdings, Inc. (MEDP)?
- The debt to assets ratio for MEDP stock is 0.13%.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle